HER2 and central nervous system metastasis in patients with breast cancer

Research output: Contribution to journalArticlepeer-review


We report a case of a patient who developed a central nervous system (CNS) metastasis 17 months after surgery and adjuvant therapy for stage II breast cancer. The HER2 status of the primary tumor as determined by immunohistochemistry (IHC) was 1+, and fluorescence in situ hybridization (FISH) performed retrospectively showed a borderline-negative result (ratio, 1:9), although HER2 amplification was present in a minority of breast cancer cells. By contrast, the HER2 status of the CNS metastasis was positive by IHC (3+) and FISH (ratio, 3:7). This report discusses the possibility that, for metastatic invasion into the CNS, clonal selection may occur, favoring HER2-positive cell clones.

Original languageEnglish
Pages (from-to)232-234
Number of pages3
JournalClinical Breast Cancer
Issue number3
Publication statusPublished - 2004


  • Ductal carcinoma
  • HER2/neu
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'HER2 and central nervous system metastasis in patients with breast cancer'. Together they form a unique fingerprint.

Cite this